SanBio Company Limited
SanBio Company Limited
Your view on SNBIF
Overview
What the company does, where it operates, and who runs it.
About SanBio Company Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Keita Mori
- Headquarters
- St. Luke Tower, Tokyo, JP
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Keita Mori
- Headquarters
- St. Luke Tower, Tokyo, JP
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan.
Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.
The company was founded in 2001 and is headquartered in Tokyo, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for SanBio Company Limited, and the rating behind it. SNBIF last traded at $16.45; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SanBio Company Limited. Starting points for SanBio Company Limited: EPS -$40.33, beta -0.03 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SanBio Company Limited. SanBio Company Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SanBio Company Limited. Trailing twelve-month EPS for SanBio Company Limited stands at -$40.33. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SanBio Company Limited. SanBio Company Limited has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SanBio Company Limited valued side by side against its closest peers. SanBio Company Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold SanBio Company Limited, and how their positions are changing. At a $1.28B market value, institutional positions materially move SanBio Company Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by SanBio Company Limited executives and directors. Shares of SanBio Company Limited have traded between $3.85 and $16.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming SanBio Company Limited. SanBio Company Limited is a $1.28B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming SanBio Company Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SanBio Company Limited. Coverage tracks SanBio Company Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.